INSM:NGS-Insmed Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 72.48

Change

0.00 (0.00)%

Market Cap

USD 0.88B

Volume

0.88M

Analyst Target

USD 45.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insmed Inc is a biopharmaceutical company. The Company is developing ARIKAYCE for inhalation (LAI), for patients with nontuberculous mycobacteria lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 92.70B
ARGX argenx NV ADR

N/A

USD 35.89B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 30.38B
BGNE BeiGene Ltd

N/A

USD 22.85B
MRNA Moderna Inc

N/A

USD 21.00B
UTHR United Therapeutics Corporatio..

N/A

USD 16.70B
RPRX Royalty Pharma Plc

N/A

USD 15.14B
INCY Incyte Corporation

N/A

USD 14.67B
SMMT Summit Therapeutics PLC

N/A

USD 13.75B

ETFs Containing INSM

FCUS Pinnacle Focused Opportun.. 4.04 % 0.00 %

N/A

USD 0.04B
PTH Invesco DWA Healthcare Mo.. 3.92 % 0.60 %

N/A

USD 0.14B
CURE:AU ETFS S&P Biotech ETF 2.46 % 0.00 %

N/A

USD 0.04B
VTWG Vanguard Russell 2000 Gro.. 0.78 % 0.20 %

N/A

USD 1.03B
XRS2:SW Xtrackers Russell 2000 UC.. 0.42 % 0.00 %

N/A

USD 1.54B
R2US:SW SPDR® Russell 2000 US Sm.. 0.42 % 0.00 %

N/A

USD 4.16B
RSSL Global X Funds 0.41 % 0.00 %

N/A

USD 1.43B
VTWO Vanguard Russell 2000 Ind.. 0.39 % 0.15 %

N/A

USD 12.32B
ITWO 0.37 % 0.00 %

N/A

N/A
UWM ProShares Ultra Russell20.. 0.31 % 0.95 %

N/A

USD 0.54B
URTY ProShares UltraPro Russel.. 0.22 % 0.95 %

N/A

USD 0.48B
HDG ProShares Hedge Replicati.. 0.00 % 0.95 %

N/A

USD 0.03B
IWM iShares Russell 2000 ETF 0.00 % 0.19 %

N/A

N/A
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

N/A

N/A
JKJ 0.00 % 0.25 %

N/A

N/A
JKK 0.00 % 0.30 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

N/A

USD 1.19B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.00 %

N/A

USD 10.02B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

N/A

USD 3.41B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

N/A

USD 3.41B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

N/A

USD 1.52B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

N/A

USD 1.52B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 3.41B
XRS2:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

N/A

USD 1.19B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 2.91B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

N/A

USD 1.19B
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

N/A

USD 2.91B
ISCG iShares Morningstar Small.. 0.00 % 0.00 %

N/A

USD 0.61B
ISCB iShares Morningstar Small.. 0.00 % 0.00 %

N/A

USD 0.23B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9,255.28% 91% A- 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 9,255.28% 91% A- 97% N/A
Trailing 12 Months  
Capital Gain 11,381.98% 92% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 11,381.98% 92% A 97% N/A
Trailing 5 Years  
Capital Gain 16,755.81% 94% A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 16,755.81% 94% A 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 104.04% N/A N/A 95% A
Dividend Return 104.04% N/A N/A 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 948.98% N/A N/A 4% F
Risk Adjusted Return 10.96% N/A N/A 47% F
Market Capitalization 0.88B 98% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 320.87 1% 0%
Price / Cash Flow Ratio -23.23 93% 90%
Price/Free Cash Flow Ratio -6.05 82% 84%
Management Effectiveness  
Return on Equity -1,453.41% 5% 2%
Return on Invested Capital -69.94% 42% 16%
Return on Assets -24.77% 63% 21%
Debt to Equity Ratio -348.07% 97% 97%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.